Core Competencies
Vector System
BBM has independently developed a variety of novel engineered adeno-associated virus (AAV) vectors; relative to conventional AAV vectors, the novel AAV vectors have higher transduction efficiency, better tissue-specificity, and lower immunogenicity.
Product Pipeline
BBM has established an extensive R&D pipeline covering a wide range of unmet medical needs in therapeutic areas such as hemophilia, hereditary muscle disease, Parkinson's disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted IND filings. The NDA of BBM-H901, a gene therapy for the treatment of adult patients with hemophilia B, has been accepted by the NMPA of China.
In-house Manufacturing
BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production site, with an area of 15,000sqm, for gene therapies in China.